Cascade of care among people with hepatitis B in New South Wales, Australia.
HBV DNA testing
care cascade
data linkage
hepatitis B virus
treatment uptake
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
18
07
2023
received:
22
05
2023
accepted:
27
07
2023
medline:
17
11
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) care cascade characterisation is important for monitoring HBV elimination progress. This study evaluated care cascade and factors associated with HBV DNA testing and treatment in New South Wales, Australia. HBV care cascade were determined through linkage of HBV notifications (1993-2017) to Medicare and pharmaceutical benefits schemes (2010-2018). Timely HBV DNA testing was within 4 weeks of HBV notification. Multivariate Cox proportional hazards regression evaluated factors associated with HBV DNA testing and treatment. Among 15,202 people with HBV notification, 10,479 (69%) were tested for HBV DNA. A total of 3179 (21%) initiated HBV treatment. HBV DNA testing was more likely among age ≥45 years (adjusted hazard ratio [aHR] 1.07, 95% CI: 1.02, 1.12), hepatocellular carcinoma (HCC) (aHR 1.23, 95% CI: 1.01, 1.50), coinfection (aHR 1.61, 95% CI: 1.23, 2.09), later notification (2014-2017) (aHR 1.21, 95% CI: 1.16, 1.26) and less likely among females (aHR 0.95, 95% CI: 0.91, 0.99), history of alcohol use disorder (AUD) (aHR 0.77, 95% CI: 0.66, 0.89), HCV coinfection (aHR .62, 95% CI: 0.55, 0.70) and Indigenous peoples (aHR 0.84, 95% CI: 0.71, 0.98). HBV treatment was associated with age ≥45 years (aHR 1.35, 95% CI: 1.24, 1.48), decompensated cirrhosis (aHR 2.07, 95% CI: 1.62, 2.65), HCC (aHR 2.96, 95% CI: 2.35, 3.74), HIV coinfection (aHR 4.27, 95% CI: 3.43, 5.31) and later notification (2014-2017) (aHR 1.37, 95% CI: 1.26, 1.47). HBV treatment was less likely among females (aHR 0.68, 95% CI: 0.63, 0.73) and Indigenous peoples (aHR 0.58, 95% CI: 0.42, 0.80). HBV DNA testing and treatment coverage have increased, but remain sub-optimal among some key populations.
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
926-938Subventions
Organisme : Department of Health and Aged Care, Australian Government
Organisme : National Health and Medical Research Council
Organisme : New South Wales Ministry of Health
Informations de copyright
© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
Références
MMWR Morb Mortal Wkly Rep. 2018 Jul 20;67(28):773-777
pubmed: 30025413
BMC Public Health. 2015 Feb 15;15:151
pubmed: 25886390
Lancet. 2006 Sep 9;368(9539):938-45
pubmed: 16962883
Ann Intern Med. 2017 Jun 06;166(11):792-798
pubmed: 28437794
J Viral Hepat. 2023 Mar;30(3):250-261
pubmed: 36537024
J Hepatol. 2016 Sep;65(3):618-30
pubmed: 27155530
J Hepatol. 2021 Feb;74(2):293-302
pubmed: 32931879
Med J Aust. 2022 May 16;216(9):478-486
pubmed: 35249220
Hepatology. 2016 Jan;63(1):284-306
pubmed: 26566246
Dig Dis Sci. 2016 Feb;61(2):618-25
pubmed: 26660679
Hepatology. 2010 Mar;51(3):759-66
pubmed: 20140950
J Hepatol. 2015 May;62(5):1061-7
pubmed: 25634330
N Engl J Med. 2013 Apr 25;368(17):1655-6
pubmed: 23614598
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
Hepatology. 2020 Apr;71(4):1170-1181
pubmed: 31419332
Curr Med Res Opin. 2015 May;31(5):925-37
pubmed: 25697811
BMC Health Serv Res. 2012 Jan 23;12:18
pubmed: 22270080
Liver Int. 2019 Dec;39(12):2261-2272
pubmed: 31444846
BMC Infect Dis. 2018 May 9;18(1):215
pubmed: 29743015
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403
pubmed: 29599078
Aust N Z J Public Health. 2015 Jun;39(3):255-9
pubmed: 25716519
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829
pubmed: 35738290
World J Clin Cases. 2019 Aug 26;7(16):2269-2286
pubmed: 31531321
Med J Aust. 2021 Aug 2;215(3):103-105.e1
pubmed: 34120343
JHEP Rep. 2022 Aug 06;4(10):100552
pubmed: 36119722
Aust N Z J Public Health. 2023 Feb;47(1):100011
pubmed: 36638581
J Hepatol. 2018 Sep;69(3):718-735
pubmed: 29777749
J Viral Hepat. 2023 Dec;30(12):926-938
pubmed: 37553801
Med J Aust. 2016 Apr 18;204(7):268-72
pubmed: 27078601
Hepatology. 2022 Mar;75(3):673-689
pubmed: 34537985
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Viruses. 2022 Jul 08;14(7):
pubmed: 35891474
J Hepatol. 2019 Aug;71(2):281-288
pubmed: 31078544
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875